Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues
Nick Beije, Wassim Abida, Emmanuel S. Antonarakis, et al.
European Urology (2023) Vol. 84, Iss. 3, pp. 253-256
Closed Access | Times Cited: 17

Showing 17 citing articles:

Development of PARP inhibitors in advanced prostate cancer
María T. Bourlon, Paola Valdez, Elena Castro
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 21
The Role of Extracellular Vesicles in the Treatment of Prostate Cancer
Cong Hu, Qi Chen, Tianyang Wu, et al.
Small (2024)
Closed Access | Times Cited: 4
PARP inhibitors in prostate cancers, is it time for combinations?
Diego Teyssonneau, Charles Dariane, Éric Barret, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 4
PARP inhibitors for prostate cancer
Ossian Longoria, Nick Beije, Johann S. de Bono
Seminars in Oncology (2023) Vol. 51, Iss. 1-2, pp. 25-35
Open Access | Times Cited: 7
PARP inhibitors alone or in combination for prostate cancer
Maria D. Fenor de la Maza, Jose Luis Pérez‐Gracia, B. Miñana, et al.
Therapeutic Advances in Urology (2024) Vol. 16
Open Access | Times Cited: 2
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer
Sumaira Sardar, Christopher McNair, Lakshmi Ravindranath, et al.
Oncogene (2024)
Open Access | Times Cited: 2
Predictive and prognostic biomarkers in urological tumours
Alessia Cimadamore, Carmine Franzese, Carla Di Loreto, et al.
Pathology (2023) Vol. 56, Iss. 2, pp. 228-238
Open Access | Times Cited: 6
Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits
Ravi A. Madan, Fatima Karzai, David J. VanderWeele, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 36, pp. 5501-5504
Closed Access | Times Cited: 5
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer
Mariangela Calabrese, Isabella Saporita, Fabio Turco, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 78-78
Open Access | Times Cited: 4
PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer
Moriah Cunningham, Matthew J. Schiewer
Cancer Research (2024) Vol. 84, Iss. 13, pp. 2049-2059
Open Access | Times Cited: 1
Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study
Sijin Chen, Dewen Zhong, Chenbo Yu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Internal Overview of Prostatic Cancer Cases and Quality of BRCA1 and BRCA2 NGS Data from the FFPE Tissue
E. Antolini, Alessandra Filosa, Matteo Santoni, et al.
Diagnostics (2024) Vol. 14, Iss. 18, pp. 2067-2067
Open Access | Times Cited: 1
Precision Medicine in Castration-Resistant Prostate Cancer: Advances, Challenges, and the Landscape of PARPi Therapy—A Narrative Review
George Dimitrov, Radoslav Mangaldzhiev, Chavdar Slavov, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2184-2184
Open Access | Times Cited: 1
Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not
Daniel A. González‐Padilla, José Daniel Subiela
European Urology (2023) Vol. 85, Iss. 1, pp. 1-2
Open Access | Times Cited: 2
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer
Sumaira Sardar, Christopher McNair, Lakshmi Ravindranath, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Cell-free DNA sequencing sheds additional insights on BRCA-altered metastatic castration-resistant prostate cancer
Soha Bazyar, Philip Sutera, Matthew P. Deek, et al.
EBioMedicine (2023) Vol. 95, pp. 104756-104756
Open Access
Mise au point et stratégies thérapeutiques dans le cancer de la prostate avancé et métastatique
Chloé Denis, Brieuc Sautois
Médecine Nucléaire (2023) Vol. 47, Iss. 6, pp. 300-308
Open Access
Page 1

Scroll to top